Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7186
Title: | Chemotherapy in cutaneous melanoma: Is there still a role? |
Authors: | Pham, J. P.;Joshua, A. M.;da Silva, Ines Pires;Dummer, R.;Goldinger, S. M. |
WSLHD Author: | da Silva, Ines Pires |
Issue Date: | 2023 |
Citation: | Current Oncology Reports 25(6):609-621, 2023 |
Abstract: | PURPOSE OF REVIEW: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined. RECENT FINDINGS: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal. Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7186 |
DOI: | https://dx.doi.org/10.1007/s11912-023-01385-6 |
Journal: | Current Oncology Reports |
Type: | Journal Article |
Study or Trial: | Review |
Department: | Oncology |
Facility: | Blacktown Westmead |
Affiliated Organisations: | Medical Oncology, The Kinghorn Cancer Centre, St. Vincent�??s Hospital Sydney, Darlinghurst, NSW, Australia School of Clinical Medicine, UNSW Medicine and Health, St Vincent�??s Hospital, Darlinghurst, NSW, Australia Melanoma Institute Australia, The University of Sydney, Wollstonecraft, NSW, Australia Medical Oncology, Blacktown Hospital, Blacktown, NSW, Australia Department of Dermatology, University Hospital Zurich, R��mistrasse 100, 8091 Zurich, Switzerland Faculty of Medicine, University of Zurich, Zurich, Switzerland |
Keywords: | Chemotherapy Immune checkpoint inhibitor Melanoma |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.